Placental CAR-MAIT Cell Composition for Stronger Persistence
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing CAR-T cell therapies using peripheral blood and cord blood MAIT cells have limitations in effector activity and survivability, which can impact their therapeutic efficacy in treating various diseases and conditions.
Innovation Solution
Development of placental MAIT cells engineered to express a chimeric antigen receptor (CAR) with enhanced effector activity and survivability, characterized by high expression of TCRVα7.2+ and CD161, capable of recognizing specific antigens such as tumor, microbial, or autoimmune targets, and optimized for cell therapy applications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If peripheral blood and cord blood MAIT cells are used for CAR-T cell therapy, then the therapy can be implemented with available cell sources, but the effector activity and survivability are limited
Solution Approach 1:
The patent changes the source parameter of MAIT cells from peripheral blood or cord blood to placental tissue. This parameter change results in MAIT cells with enhanced effector activity and survivability characteristics, directly resolving the contradiction between available cell sources and therapeutic performance.
2Reliability
If placental MAIT cells are engineered to express CAR, then effector activity and survivability are enhanced, but the complexity of cell engineering increases
Solution Approach 1:
The patent engineers placental MAIT cells to express chimeric antigen receptors that can target multiple types of diseases including tumors, infections, fibrotic diseases, and autoimmune disorders. This multi-functionality approach justifies the engineering complexity by providing a universal cell therapy platform for diverse applications.
Data Source
AI summary
This invention is directed in one main aspect to a cell composition comprising a population of engineered mucosal-associated invariant T (MAIT) cells derived from placental tissue expressing an exogenous chimeric antigen receptor (CAR). The invention further discloses a unique placental MAIT cell population, cell compositions comprising the MAIT cell population, and methods of use.